Celine Colacios

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells.

The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells.

Journal: Journal of extracellular vesicles

Published: July 01, 2025

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

Journal: Immunity

Published: January 21, 2025

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.

Journal: International journal of cancer

Published: September 19, 2024

Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.

Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.

Journal: Nature reviews. Rheumatology

Published: July 06, 2021

Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer.

Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer.

Journal: Cancers

Published: June 30, 2021

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 02, 2020

Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.

Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.

Journal: Cancer immunology research

Published: April 25, 2020

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.

Journal: Frontiers in immunology

Published: October 07, 2019

Anti-TNF, a magic bullet in cancer immunotherapy?

Anti-TNF, a magic bullet in cancer immunotherapy?

Journal: Journal for immunotherapy of cancer

Published: August 30, 2019

The TNF Paradox in Cancer Progression and Immunotherapy.

The TNF Paradox in Cancer Progression and Immunotherapy.

Journal: Frontiers in immunology

Published: March 08, 2019

Anti-TNFα antibodies in melanoma immunotherapy

Anti-TNFα antibodies in melanoma immunotherapy

Journal: Medecine sciences : M/S

Published: November 20, 2018

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Journal: Frontiers in pharmacology

Published: November 19, 2018

Showing 1-12 of 26

Last Updated: 09/26/2026